Your browser is no longer supported. Please, upgrade your browser.
Settings
MTNB Matinas BioPharma Holdings, Inc. daily Stock Chart
MTNB [NYSE]
Matinas BioPharma Holdings, Inc.
Index- P/E- EPS (ttm)-0.13 Insider Own2.00% Shs Outstand185.71M Perf Week7.86%
Market Cap280.42M Forward P/E- EPS next Y-0.15 Insider Trans- Shs Float178.49M Perf Month-11.70%
Income-16.40M PEG- EPS next Q-0.03 Inst Own16.60% Short Float3.82% Perf Quarter112.20%
Sales0.09M P/S3122.32 EPS this Y57.90% Inst Trans0.00% Short Ratio2.10 Perf Half Y93.32%
Book/sh0.22 P/B6.86 EPS next Y-16.70% ROA-40.10% Target Price3.90 Perf Year55.67%
Cash/sh0.18 P/C8.58 EPS next 5Y- ROE-62.80% 52W Range0.58 - 2.49 Perf YTD-33.48%
Dividend- P/FCF- EPS past 5Y-5.70% ROI-211.00% 52W High-38.76% Beta2.45
Dividend %- Quick Ratio13.10 Sales past 5Y- Gross Margin- 52W Low162.12% ATR0.20
Employees15 Current Ratio13.10 Sales Q/Q- Oper. Margin- RSI (14)47.41 Volatility8.61% 10.97%
OptionableNo Debt/Eq0.01 EPS Q/Q15.40% Profit Margin- Rel Volume1.89 Prev Close1.51
ShortableYes LT Debt/Eq0.00 EarningsFeb 12 BMO Payout- Avg Volume3.24M Price1.52
Recom1.80 SMA20-13.40% SMA50-0.90% SMA20052.85% Volume754,178 Change0.99%
Jan-24-20Initiated SunTrust Buy
Jan-23-20Initiated SunTrust Buy
Jan-09-20Initiated Aegis Capital Buy $3.50
Jun-26-19Initiated H.C. Wainwright Buy $4
Jan-21-20 08:41AM  Prospects Appear Bright for Small Drug Industry in 2020 Zacks
Jan-14-20 11:21AM  Matinas BioPharma Announces Closing of Public Offering of Common Stock GlobeNewswire
Jan-10-20 08:00AM  Matinas BioPharma Announces Pricing of Public Offering of Common Stock GlobeNewswire -23.56%
07:13AM  The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga
Jan-09-20 04:05PM  Matinas BioPharma Announces Proposed Public Offering of Common Stock GlobeNewswire +16.46%
Jan-07-20 04:56AM  Edited Transcript of MTNB earnings conference call or presentation 13-Nov-19 1:00pm GMT Thomson Reuters StreetEvents -14.01%
Jan-03-20 02:13PM  Read This Before Selling Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Shares Simply Wall St.
Dec-22-19 01:30PM  Did Hedge Funds Drop The Ball On Matinas Biopharma Holdings, Inc. (MTNB) ? Insider Monkey
Dec-20-19 04:41AM  Amarin Stock is at Sky-High Levels Already Assumes All the Good News InvestorPlace
Dec-12-19 07:00AM  Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform GlobeNewswire
Nov-18-19 10:29AM  Matinas Rides Amarin's Coattails as Vascepa Wins FDA Panel Vote GuruFocus.com +19.23%
07:30AM  Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-15-19 08:54AM  Amarin Stock Is Rising After Favorable Vote on Fish-Based Heart Drug Barrons.com +15.56%
08:25AM  Amarin shares rise in premarket trading on FDA adcom vote for new label MarketWatch
Nov-13-19 07:45AM  Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:30AM  Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-06-19 07:30AM  Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, 2019 GlobeNewswire
Oct-28-19 03:17PM  Should You Be Concerned About Matinas BioPharma Holdings, Inc.'s (NYSEMKT:MTNB) Historical Volatility? Simply Wall St. +6.20%
Oct-14-19 07:00AM  Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis GlobeNewswire
Oct-07-19 07:00AM  Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis GlobeNewswire
Sep-27-19 08:00AM  Matinas BioPharma to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire
Sep-25-19 07:00AM  Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa® GlobeNewswire
Sep-20-19 09:57AM  Matinas BioPharma Holdings (NYSEMKT:MTNB) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +7.00%
Aug-28-19 07:30AM  Matinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire +6.35%
Aug-23-19 07:35AM  Edited Transcript of MTNB earnings conference call or presentation 13-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-14-19 11:34AM  Is Matinas BioPharma Holdings (NYSEMKT:MTNB) Using Debt Sensibly? Simply Wall St.
Aug-13-19 08:05AM  Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Tops Revenue Estimates Zacks +8.39%
06:45AM  Matinas BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
06:30AM  Matinas Biopharma Holdings, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-19 10:30AM  Will Matinas Biopharma Holdings, Inc. (MTNB) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-30-19 07:30AM  Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2019 Operational and Financial Results on August 13, 2019 GlobeNewswire
Jul-25-19 07:30AM  Matinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis GlobeNewswire
Jul-09-19 12:13PM  What Kind Of Investor Owns Most Of Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB)? Simply Wall St.
Jun-03-19 08:05AM  Matinas BioPharma to Present at the 9th Annual LD Micro Invitational GlobeNewswire
May-29-19 01:29AM  Edited Transcript of MTNB earnings conference call or presentation 14-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-28-19 08:00AM  Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio GlobeNewswire
May-22-19 09:29AM  Have Insiders Been Buying Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Shares? Simply Wall St.
May-21-19 08:00AM  Matinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019 GlobeNewswire
May-15-19 07:00AM  Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates GlobeNewswire
May-14-19 07:00AM  Matinas BioPharma Provides Corporate Update and Reports First Quarter 2019 Financial Results GlobeNewswire +5.37%
May-08-19 08:05AM  Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019 GlobeNewswire
May-02-19 08:35AM  Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019 GlobeNewswire
May-01-19 08:35AM  Matinas BioPharma Selected to Present at the BioNJ Ninth Annual BioPartnering Conference GlobeNewswire
Apr-11-19 11:07AM  Edited Transcript of MTNB earnings conference call or presentation 2-Apr-19 12:00pm GMT Thomson Reuters StreetEvents
Apr-02-19 07:05AM  Matinas BioPharma Reports 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-26-19 08:00AM  Matinas BioPharma to Announce Full-Year 2018 Operational and Financial Results on April 2, 2019 GlobeNewswire +7.14%
Mar-18-19 08:35AM  Matinas BioPharma to Present at the 31st Annual ROTH Conference Business Wire
Mar-15-19 08:45AM  Matinas BioPharma Announces Pricing of Public Offering of Common Stock Business Wire +8.33%
Mar-14-19 05:02PM  Matinas BioPharma Announces Proposed Public Offering of Common Stock Business Wire
Feb-25-19 08:05AM  Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer GlobeNewswire
Jan-16-19 09:00AM  Biotech Breaking Out ACCESSWIRE +7.46%
Jan-10-19 08:00AM  Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform GlobeNewswire +14.47%
Jan-03-19 08:20AM  Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer GlobeNewswire
Dec-20-18 08:35AM  Matinas BioPharma to Present at Biotech Showcase 2019 GlobeNewswire +13.34%
Dec-19-18 08:35AM  Matinas BioPharma Appoints Harold E. Bays, M.D. to its Cardiovascular Health Scientific Advisory Board GlobeNewswire
Dec-06-18 09:00AM  Matinas BioPharma Assembles World Class Scientific Advisory Board to Guide Clinical Development Strategy of Potential Best-in-Class Prescription-Only Omega-3, MAT9001 GlobeNewswire
Nov-26-18 07:55AM  Detailed Research: Economic Perspectives on Sunstone Hotel Investors, Acadia Realty Trust, Matinas Biopharma, Compass Diversified, Aspen Insurance, and Superior Drilling Products What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-23-18 01:48PM  How Does Investing In Matinas BioPharma Holdings Inc (NYSEMKT:MTNB) Impact The Volatility Of Your Portfolio? Simply Wall St.
Nov-13-18 09:15AM  4 Stocks To Watch As Healthcare Technology Industry Is Expecting Rapid Growth Through 2025 ACCESSWIRE -13.19%
Nov-12-18 08:45AM  3 Healthcare Stocks Pushing The Boundaries Of Innovation: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Matinas BioPharma Holdings, Inovalon Holdings ACCESSWIRE -13.86%
07:00AM  Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Oct-18-18 08:00AM  Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001 Providing Protection Through 2033 GlobeNewswire +31.82%
Oct-16-18 08:00AM  Matinas BioPharma to Present at the 8th Annual Partnership Opportunities in Drug Delivery Conference GlobeNewswire +5.73%
Oct-15-18 08:01AM  Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team GlobeNewswire
Sep-25-18 08:00AM  Matinas BioPharma to Present at the MicroCap Conference GlobeNewswire +18.86%
Sep-06-18 08:01AM  Matinas BioPharma Announces Appointment of Industry Leader Patrick G. LePore to Board of Directors GlobeNewswire
Sep-05-18 08:00AM  Matinas BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference GlobeNewswire -9.26%
Aug-16-18 08:00AM  Matinas BioPharma to Present at the U.S. FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop GlobeNewswire
Aug-10-18 08:15AM  Matinas BioPharma Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-25-18 07:40AM  Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-09-18 09:15AM  NIH and Matinas BioPharma Announce Research Collaboration to Identify Novel HIV Therapy Utilizing LNC Platform Delivery Technology GlobeNewswire +12.05%
Jun-22-18 08:30AM  Matinas BioPharma Announces Closing of $8.0 Million Public Offering GlobeNewswire -5.27%
Jun-19-18 08:00AM  Matinas BioPharma Announces Pricing of $8.0 Million Public Offering GlobeNewswire -9.14%
Jun-12-18 08:00AM  Matinas BioPharma to Present at the 20th ICHS Symposium on Infections in the Immunocompromised Host GlobeNewswire
Jun-06-18 12:26PM  Matinas BioPharma Holdings Inc (NYSEMKT:MTNB): Is Breakeven Near? Simply Wall St. +9.93%
07:35AM  Matinas BioPharma to Present Preclinical Data at ASM Microbe 2018 Further Demonstrating the Broad Utility of its LNC Platform GlobeNewswire
May-10-18 07:05AM  Matinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-07-18 08:05AM  Matinas BioPharma to Host Quarterly Update Conference Call GlobeNewswire
May-01-18 08:05AM  Matinas BioPharma Selected to Present at the BioNJ Eighth Annual BioPartnering Conference GlobeNewswire +35.33%
Apr-19-18 08:05AM  Matinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious Disease GlobeNewswire
Mar-26-18 04:45PM  Matinas BioPharma Reports 2017 Financial Results GlobeNewswire
Mar-19-18 06:30AM  Matinas BioPharma Holdings, Inc. to Host Earnings Call ACCESSWIRE
Mar-16-18 05:00PM  Matinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate Update GlobeNewswire
Mar-15-18 08:00AM  Matinas BioPharma to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-12-18 08:05AM  Matinas BioPharma to Host 2017 Financial Results and Corporate Update Conference Call and Webcast GlobeNewswire
Jan-08-18 07:01AM  Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis GlobeNewswire
Dec-14-17 07:01AM  Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors GlobeNewswire
Nov-15-17 07:35AM  Matinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update GlobeNewswire
Oct-11-17 08:05AM  Matinas BioPharma to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference GlobeNewswire
Sep-19-17 09:20AM  Matinas BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-12-17 07:30AM  Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001 GlobeNewswire
Aug-08-17 06:05AM  Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501 GlobeNewswire
05:50AM  Investor Network: Matinas BioPharma Holdings, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 08:05AM  Matinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference GlobeNewswire
Aug-01-17 08:30AM  Matinas BioPharma to Host Quarterly Update Conference Call GlobeNewswire
Jun-26-17 01:15PM  Here's Why Matinas BioPharma Holdings Inc. Is Losing Ground Today Motley Fool
06:05AM  Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis GlobeNewswire
Jun-03-17 04:00PM  Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis GlobeNewswire
Jun-02-17 04:01PM  Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis GlobeNewswire
Jun-01-17 07:05AM  Matinas BioPharma to Present at the 2017 Jefferies Global Healthcare Conference GlobeNewswire
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company develops products using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals, which could encapsulate small molecules, gene therapies, vaccines, proteins, and peptides. The company's lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. In addition, it provides MAT2501, an orally administered cochleate formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with ViiV Healthcare for the treatment and care for people living with human immunodeficiency virus. The company was founded in 2013 and is based in Bedminster, New Jersey.